Background: CD5L (CD5 molecular-like) plays an important role in lipid metabolism and immune regulation. This study aimed to investigate the roles of CD5L on liver hepatocellular carcinoma (LIHC). Methods: We analyzed...Background: CD5L (CD5 molecular-like) plays an important role in lipid metabolism and immune regulation. This study aimed to investigate the roles of CD5L on liver hepatocellular carcinoma (LIHC). Methods: We analyzed the CD5L mRNA expression and its potential prognostic value based on The Cancer Genome Atlas and Gene Expression Omnibus databases. Immunohistochemical analysis was used to investigate the CD5L levels in LIHC tissues. Serum CD5L levels in LIHC were detected by enzyme-linked immunosorbent assay. Cell Counting Kit-8 (CCK-8) assay was used to investigate the effect of CD5L treatment on HepG2 and QSG-7701 cell proliferation. CD5L expression correlated genes were exhumed based on the LinkedOmics. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses for CD5L associated genes were performed. The correlation between CD5L and tumor immune infiltration was analyzed by using Tumor Immune Estimation Resource (TIMER) 2.0. Results: CD5L mRNA and protein levels were significantly decreased in LIHC tumor tissue compared with non-tumor control tissues. Moreover, serum CD5L levels were significantly lower in LIHC patients than that in healthy subjects. Gene Expression Profiling Interactive Analysis 2 and Kaplan-Meier plotter analysis showed that a high-CD5L expression was correlated with favorable overall survival in LIHC patients, except the LIHC patients with hepatitis virus. CCK-8 results showed that CD5L treatment significantly decreased HepG2 cell proliferation in a concentration-dependent manner, and CD5L treatment had no effect on the proliferation of non-tumor hepatocyte line QSG-7701. CD5L associated genes were enriched in the immune response biological process, and CD5L expression levels were positively correlated with the immune infiltrates of CD8 ^(+) T cell and M1 macrophage cells but negatively correlated with CD4 ^(+) T cells and M0 macrophage cell infiltration. Conclusions: Exogenous CD5L inhibits cell proliferation of hepatocellular carcinoma. CD5L may act as a role of prognostic marker.展开更多
目的探讨C-MYC、bcl-2、bcl-6蛋白的表达与原发性CD5阳性的弥漫性大B细胞淋巴瘤(CD5-positive diffuse large B cell lymphoma,CD5+DLBCL)患者临床病理特征之间的关系。方法收集2013年2月至2018年9月上海交通大学医学院附属瑞金医院初...目的探讨C-MYC、bcl-2、bcl-6蛋白的表达与原发性CD5阳性的弥漫性大B细胞淋巴瘤(CD5-positive diffuse large B cell lymphoma,CD5+DLBCL)患者临床病理特征之间的关系。方法收集2013年2月至2018年9月上海交通大学医学院附属瑞金医院初治诊断为原发性CD5+DLBCL标本57例,采用HE染色、免疫组织化学技术及荧光原位杂交(FISH)法,检测原发性CD5+DLBCL中C-MYC、bcl-2、bcl-6蛋白的表达情况,并分析其与临床病理特征之间的关系。结果57例原发性CD5+DLBCL中,男性27例,女性30例,发病年龄35~99岁。C-MYC、bcl-2、bcl-6蛋白表达阳性率分别为50.9%(29/57)、84.2%(48/57)、75.4%(43/57),其中C-MYC和bcl-2双表达阳性率为40.4%(23/57);其在患者性别、临床分期、血清乳酸脱氢酶(LDH)水平、β2微球蛋白水平、国际预后指数(IPI)评分、B症状、骨髓侵犯和中枢神经系统(CNS)复发等临床特征之间差异无统计学意义(P>0.05);单因素生存分析显示:C-MYC阴性患者中位总生存率显著高于阳性患者(P=0.010),双表达阴性患者中位总生存率显著高于阳性患者(P=0.008),bcl-6阳性患者中位总生存率显著高于阴性患者,差异具有统计学意义(P=0.021),bcl-2蛋白表达与预后无明显相关性(P>0.05);Cox模型多因素分析显示,C-MYC蛋白表达可作为原发性CD5+DLBCL患者总生存率的独立预测指标(P=0.034)。结论C-MYC、bcl-2、bcl-6蛋白在原发性CD5+DLBCL的预后价值中,bcl-2表达对预后无影响,bcl-6阳性组预后较好,C-MYC蛋白表达可作为预测原发性CD5+DLBCL患者预后的独立有效指标,但对于原发性CD5+DLBCL患者中,C-MYC、bcl-2及bcl-6蛋白的表达与C-MYC、bcl-2及bcl-6基因重排之间的关系,还有待扩大样本量进一步深入探讨。展开更多
目的:探讨沙丁胺醇联合布地奈德雾化吸入对支气管哮喘患儿血清AT-Ⅲ、CD5L以及炎症水平的影响。方法:选取我院2018年10月到2020年10月共收治的78例支气管哮喘患儿作为研究对象,将所有患儿随机分为观察组与对照组,每组39例。对照组患儿...目的:探讨沙丁胺醇联合布地奈德雾化吸入对支气管哮喘患儿血清AT-Ⅲ、CD5L以及炎症水平的影响。方法:选取我院2018年10月到2020年10月共收治的78例支气管哮喘患儿作为研究对象,将所有患儿随机分为观察组与对照组,每组39例。对照组患儿应用布地奈德雾化吸入治疗,观察组患儿应用沙丁胺醇联合布地奈德雾化吸入治疗,对比两组患儿的治疗效果、治疗前后的FeNO、肺功能指标、血气指标、血清AT-Ⅲ、CD5L以及外周血单个核细胞NLRP3炎症小体变化情况。结果:观察组患儿的治疗总有效率为97.44%,显著高于对照组的82.05%(P<0.05);两组患儿治疗前PEF、FVC、FEV1指标对比无显著差异(P>0.05),通过治疗后观察组患儿的PEF、FVC、FEV1指标明显优于对照组,组间对比,差异具有统计学意义(P<0.05);通过对比各项肺功能指标发现,两组患儿治疗后PaO_(2)、PaCO_(2)、SaO_(2)指标对比差异均无统计学意义(P>0.05);两组患儿治疗前FeNO、AT-Ⅲ、CD5L以及外周血单个核细胞NLRP3炎症小体表达对比无明显差异(P>0.05);治疗后,观察组患儿FeNO、AT-Ⅲ水平以及NLRP3 m RNA表达均显著低于对照组,CD5L水平高于对照组(P<0.05)。结论:对支气管哮喘患儿应用沙丁胺醇联合布地奈德雾化吸入治疗,能够减轻患儿临床症状,提高治疗效果,提升患儿肺功能,稳定血气指标,减轻慢性缺氧状态,提升免疫力,降低炎症反应,值得临床应用推广。展开更多
基金fund of Tangdu Hospital(Nos.2021SHRC043,2021SHRC031)
文摘Background: CD5L (CD5 molecular-like) plays an important role in lipid metabolism and immune regulation. This study aimed to investigate the roles of CD5L on liver hepatocellular carcinoma (LIHC). Methods: We analyzed the CD5L mRNA expression and its potential prognostic value based on The Cancer Genome Atlas and Gene Expression Omnibus databases. Immunohistochemical analysis was used to investigate the CD5L levels in LIHC tissues. Serum CD5L levels in LIHC were detected by enzyme-linked immunosorbent assay. Cell Counting Kit-8 (CCK-8) assay was used to investigate the effect of CD5L treatment on HepG2 and QSG-7701 cell proliferation. CD5L expression correlated genes were exhumed based on the LinkedOmics. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses for CD5L associated genes were performed. The correlation between CD5L and tumor immune infiltration was analyzed by using Tumor Immune Estimation Resource (TIMER) 2.0. Results: CD5L mRNA and protein levels were significantly decreased in LIHC tumor tissue compared with non-tumor control tissues. Moreover, serum CD5L levels were significantly lower in LIHC patients than that in healthy subjects. Gene Expression Profiling Interactive Analysis 2 and Kaplan-Meier plotter analysis showed that a high-CD5L expression was correlated with favorable overall survival in LIHC patients, except the LIHC patients with hepatitis virus. CCK-8 results showed that CD5L treatment significantly decreased HepG2 cell proliferation in a concentration-dependent manner, and CD5L treatment had no effect on the proliferation of non-tumor hepatocyte line QSG-7701. CD5L associated genes were enriched in the immune response biological process, and CD5L expression levels were positively correlated with the immune infiltrates of CD8 ^(+) T cell and M1 macrophage cells but negatively correlated with CD4 ^(+) T cells and M0 macrophage cell infiltration. Conclusions: Exogenous CD5L inhibits cell proliferation of hepatocellular carcinoma. CD5L may act as a role of prognostic marker.
文摘目的探讨C-MYC、bcl-2、bcl-6蛋白的表达与原发性CD5阳性的弥漫性大B细胞淋巴瘤(CD5-positive diffuse large B cell lymphoma,CD5+DLBCL)患者临床病理特征之间的关系。方法收集2013年2月至2018年9月上海交通大学医学院附属瑞金医院初治诊断为原发性CD5+DLBCL标本57例,采用HE染色、免疫组织化学技术及荧光原位杂交(FISH)法,检测原发性CD5+DLBCL中C-MYC、bcl-2、bcl-6蛋白的表达情况,并分析其与临床病理特征之间的关系。结果57例原发性CD5+DLBCL中,男性27例,女性30例,发病年龄35~99岁。C-MYC、bcl-2、bcl-6蛋白表达阳性率分别为50.9%(29/57)、84.2%(48/57)、75.4%(43/57),其中C-MYC和bcl-2双表达阳性率为40.4%(23/57);其在患者性别、临床分期、血清乳酸脱氢酶(LDH)水平、β2微球蛋白水平、国际预后指数(IPI)评分、B症状、骨髓侵犯和中枢神经系统(CNS)复发等临床特征之间差异无统计学意义(P>0.05);单因素生存分析显示:C-MYC阴性患者中位总生存率显著高于阳性患者(P=0.010),双表达阴性患者中位总生存率显著高于阳性患者(P=0.008),bcl-6阳性患者中位总生存率显著高于阴性患者,差异具有统计学意义(P=0.021),bcl-2蛋白表达与预后无明显相关性(P>0.05);Cox模型多因素分析显示,C-MYC蛋白表达可作为原发性CD5+DLBCL患者总生存率的独立预测指标(P=0.034)。结论C-MYC、bcl-2、bcl-6蛋白在原发性CD5+DLBCL的预后价值中,bcl-2表达对预后无影响,bcl-6阳性组预后较好,C-MYC蛋白表达可作为预测原发性CD5+DLBCL患者预后的独立有效指标,但对于原发性CD5+DLBCL患者中,C-MYC、bcl-2及bcl-6蛋白的表达与C-MYC、bcl-2及bcl-6基因重排之间的关系,还有待扩大样本量进一步深入探讨。
文摘目的:探讨沙丁胺醇联合布地奈德雾化吸入对支气管哮喘患儿血清AT-Ⅲ、CD5L以及炎症水平的影响。方法:选取我院2018年10月到2020年10月共收治的78例支气管哮喘患儿作为研究对象,将所有患儿随机分为观察组与对照组,每组39例。对照组患儿应用布地奈德雾化吸入治疗,观察组患儿应用沙丁胺醇联合布地奈德雾化吸入治疗,对比两组患儿的治疗效果、治疗前后的FeNO、肺功能指标、血气指标、血清AT-Ⅲ、CD5L以及外周血单个核细胞NLRP3炎症小体变化情况。结果:观察组患儿的治疗总有效率为97.44%,显著高于对照组的82.05%(P<0.05);两组患儿治疗前PEF、FVC、FEV1指标对比无显著差异(P>0.05),通过治疗后观察组患儿的PEF、FVC、FEV1指标明显优于对照组,组间对比,差异具有统计学意义(P<0.05);通过对比各项肺功能指标发现,两组患儿治疗后PaO_(2)、PaCO_(2)、SaO_(2)指标对比差异均无统计学意义(P>0.05);两组患儿治疗前FeNO、AT-Ⅲ、CD5L以及外周血单个核细胞NLRP3炎症小体表达对比无明显差异(P>0.05);治疗后,观察组患儿FeNO、AT-Ⅲ水平以及NLRP3 m RNA表达均显著低于对照组,CD5L水平高于对照组(P<0.05)。结论:对支气管哮喘患儿应用沙丁胺醇联合布地奈德雾化吸入治疗,能够减轻患儿临床症状,提高治疗效果,提升患儿肺功能,稳定血气指标,减轻慢性缺氧状态,提升免疫力,降低炎症反应,值得临床应用推广。
